# ask-04 Evidence Card

- Captured: `2026-09-29T04:07:42+00:00`
- Mode: `ask`
- Execution: `local`
- Offline flag: `false`
- Model: `gemma3:1b-it-q4_K_M`
- Expected behavior: State that the local evidence is insufficient.
- Expected sources: `[]`
- Expected locators: `[]`

## Question

What percentage of Chilean patients received same-day primary care in 2026?

## Retrieved Original Passages

### S1: `vault/raw/study-guide/Healthcare in the 21st Century Study Guide through September 21 2026.docx` — section "Healthcare changes quickly and slowly at the same time"

Score: `6.709635`; query coverage: `6`

> Science can produce rapid breakthroughs, while delivery, payment, workflow, and regulation change slowly. Innovations must fit budgets, reimbursement codes, clinical workflows, data systems, and stakeholder incentives before they spread. This explains why impressive technical capability does not automatically translate into scaled patient benefit. [Class 8/26/26] Policy and regulation: public spending decisions, coverage rules, safety requirements, and CMS payment models can redirect entire markets. Economic pressure: labor, supplies, inflation, capital costs, and household affordability increase friction throughout the system. Demography and disease: aging and chronic illness increase the need for long-term management rather than episodic acute care. Science and technology: AI, biotechnology, connected devices, and data can improve care, but adoption depends on evidence, integration, liability, security, and payment. Consumer behavior: patients have more information and direct channels, yet cost, trust, and health literacy limit agency. Consolidation and new entrants: incumbents seek scale and control while technology companies, retailers, and specialized care models challenge traditional channels. Primary sources: Class 8/26/26 and PwC (2026). PwC's forecast, based on 24 health plans, projected 2026 medical cost trends of 8.5% for group plans and 7.5% for individual plans; pharmacy trend ran 2.5 percentage points higher than medical trend.

### S2: `vault/raw/course-slides/MBA297A_Reimbursement__Value_09.21.26posted.pdf` — slide 1

Score: `4.404363`; query coverage: `4`

> MBA297A–HC in 21st Century: Connect Money
> Stack to Care Journey w/Reimbursement
> Kim MacPherson, MBA/MPH
> September 21, 2026
> Executive Director, Health Management at Haas School of Business
> Distinguished Teaching Fellow

### S3: `vault/raw/course-slides/MBA297A_Structure_Costs_Value_08.31.26.pdf` — slide 1

Score: `4.095597`; query coverage: `3`

> MBA297A –HC in 21st Century:
> Overview on HC Structure & Cost
> Kim MacPherson, MBA/MPH
> August 31, 2026
> Executive Director, Health Management at Haas School of Business
> Distinguished Teaching Fellow

### S4: `vault/raw/course-slides/MBA297A_Reimbursement__Value_09.21.26posted.pdf` — slide 4

Score: `4.049403`; query coverage: `3`

> We use payment to influence behavior in the health
> system – explicit signal of priorities, goals, values
> • How something is paid for can be as important as the level of
> payment (i.e. per service/dose, per episode/case, per 100K people)
> Prospective vs. retrospective vs. concurrent
> ▪
> Certain $$ vs. conditional/contingent on performance
> ▪
> Different reimbursement levels and models co-exist for same products, services
> ▪
> also can vary by site/modality
> • People and organizations are very responsive to payment signals
> Impact can be muddled by other forces, competing goals
> ▪
> Needs to be enough payment to get and keep focus
> ▪
> Impact of the payment signal can diminish over time or with competing signals
> ▪
> Not everyone or every organization will respond in same way – goals, values,
> ▪
> risks, motivations, competing priorities can all be very different
> 4

### S5: `vault/raw/study-guide/Healthcare in the 21st Century Study Guide through September 21 2026.docx` — section "4 Why might a PBM prefer a highly rebated drug rather than the drug with the lowest list price?"

Score: `3.946696`; query coverage: `1`

> A rebate can increase the PBM's or plan's negotiated revenue and lower net plan cost, but the patient's cost sharing may still be tied to the higher list price. Opaque contracts make it difficult to see who receives the savings. [Class 9/9/26; FTC, 2024]

## Actual Displayed Answer

Insufficient evidence: the local sources do not contain enough relevant support to answer this question.

## Raw Gemma Output

```json
(model was not called because retrieval was insufficient)
```

## Run Metrics

```json
{}
```

## Assessment

- Automated structural assessment: **PASS**
- Retrieved source IDs: `["reimbursement-value-2026-09-21", "structure-costs-2026-08-31", "study-guide-2026"]`
- Citation validation: `not applicable or insufficient evidence`
- Human claim-to-passage review: `PASS — none of the retrieved passages mentions Chilean patients or the requested percentage, so the insufficient-evidence response is correct.`
- Notes: Required named term(s) not present: chilean.
